INGENITO GARY 4

4 · CATALYST PHARMACEUTICALS, INC. · Filed May 15, 2025

Form 4

Period: 2025-05-13

Chief Med. & Reg. Officer

Transactions

Exercise/Conversion
Common stock, par value $0.001 per share
2025-05-14$4.64/sh+44,000$204,160→ 112,873 total
Sale
Common stock, par value $0.001 per share
2025-05-14$23.63/sh−44,000$1,039,720→ 68,873 total
Exercise/Conversion
Options to purchase common stock
2025-05-13−200,000→ 590,282 total
Exercise: $3.42Exp: 2027-12-30→ Common Stock (200,000 underlying)
Exercise/Conversion
Options to purchase common stock
2025-05-14−44,000→ 546,282 total
Exercise: $4.64Exp: 2026-12-02→ Common Stock (44,000 underlying)
Exercise/Conversion
Common stock, par value $0.001 per share
2025-05-13$3.42/sh+200,000$684,000→ 268,873 total
Sale
Common stock, par value $0.001 per share
2025-05-13$23.68/sh−200,000$4,736,000→ 68,873 total

Footnotes (5)

[F1]Shares were sold on the open market for personal reasons and not as a result of any disagreement with the Company.
[F2]Represents a weighted average price for the shares sold. Shares were sold in a range between $23.325 and $23.93 per share.
[F3]Represents a weighted average price for the shares sold. Shares were sold in a range between $23.44 and $24.025 per share.
[F4]Options vested in three annual tranches beginning on December 30, 2021.
[F5]Options vested in three annual tranches beginning on December 2, 2020.

Documents

1 file